Introduction
============

Carbapenem-resistant *Klebsiella pneumoniae* (CRKP) infections have emerged worldwide as a serious challenge to public health ([@B18]). *K. pneumoniae* resistance to carbapenem is mainly due to the acquisition of carbapenemase, and the carbapenem-hydrolyzing *K. pneumoniae* carbapenemase (KPC) has been the enzyme most commonly identified in *K. pneumoniae* in China ([@B27]). *K. pneumoniae* can cause various types of infections, including abdominal and urinary tract infections, liver abscesses, bacteremia, and pneumonia ([@B10]). The management of infections caused by CRKP is complicated ([@B18]). In fact, carbapenemase-producing *K. pneumoniae* often carry multiple drug resistance genes that enable the strains to exhibit resistance to almost all antibiotics except colistin and tigecycline ([@B8]; [@B18]).

Tigecycline is one of the last treatment options remaining for carbapenem-resistant *Enterobacteriaceae* ([@B2]; [@B12]). A semisynthetic derivative of minocycline, tigecycline is a recent antibiotic that belongs to the glycylcycline class and can overcome the mechanisms of tetracycline resistance ([@B17]). Tigecycline is effective against most carbapenemase-producing bacteria, including *K. pneumoniae*, and has been approved in recent years for clinical use in China ([@B10]). However, resistance to tigecycline has emerged since its approval ([@B11]). The mechanism for tigecycline resistance has not yet been clearly elucidated. In Gram-negative bacteria, the enhanced expression of resistance--nodulation--cell division (RND)-type efflux pumps was associated with decreased tigecycline susceptibility ([@B16]). Over-expression of the RND efflux pumps, AcrAB and OqxAB, is one of the mechanisms reported most frequently in the *Enterobacteriaceae* species, and several global transcriptional regulators of the AraC family, namely, RamA, MarA, SoxS, and RarA, participate in tigecycline resistance via efflux pump activation ([@B22]; [@B5]; [@B24]; [@B23]). [@B15] also reported a new efflux pump operon, *kpgABC*, and identified an insertion element whose presence correlated with the *in vivo* development of tigecycline non-susceptibility in *K. pneumoniae*. The ribosomal S10 protein is also a general target (via the mutation of *rpsJ*) that has been described for its ability to cause decreased tigecycline susceptibility in both Gram-negative and Gram-positive bacteria ([@B6]; [@B4]).

Previous studies have shown that tigecycline can overcome the mechanisms of tetracycline resistance ([@B17]; [@B13]). However, [@B1] found that the *tetA* gene carried by *Salmonella* species, which imparts their tetracycline resistance and also causes reduced susceptibility to tigecycline. [@B14] discovered that evolutionary changes in TetA, TetM, and TetX can cause tigecycline resistance in *Escherichia coli* *in vitro*, and they predicted that TetX might become the most problematic future Tet determinant because it did not have adverse effects on resistance toward other tetracyclines. Most recently, [@B7] reported that widespread mutated *tetA* genes are concerning due to the possible dissemination of increased tigecycline resistance in *K. pneumoniae*.

In this study, consecutive clonal consistent *K. pneumoniae* isolates were collected from a 56-year-old female patient with duodenal papillary carcinoma who was undergoing tigecycline treatment. In the early stages of her tigecycline treatment, the isolates were susceptible to tigecycline (MIC = 1 mg/L); 13 days later, we isolated the first resistant strain with a tigecycline MIC of 32 mg/L. To the best of our knowledge, this study is the first report to present consecutive clonal consistent *K. pneumoniae* isolates while they evolved high-level resistance to tigecycline during *in vivo* treatment. Whole genome sequencing (WGS) of these isolates was completed using the Illumina HiSeq X Ten platform, and subsequent bioinformatics analyses were performed to explore the tigecycline resistance mechanism of these isolates.

Materials and Methods {#s1}
=====================

The Patient and Isolates
------------------------

A 56-year-old female patient was diagnosed with duodenal papillary carcinoma and admitted to the hospital for a Whipple operation. Following surgery, the patient contracted an abdominal infection. Initially, the patient received multiple antimicrobial treatments, including cefotaxime, levofloxacin, and imipenem. Isolates were cultured from the patient during her hospitalization. KPC-2 producing extensively drug resistant (XDR) *K. pneumoniae* susceptible only to colistin and tigecycline were isolated from both blood and ascites samples 23 days subsequent to the Whipple surgery. The antibiotic therapeutic strategy was then adjusted to that of intravenous tigecycline (a 100 mg loading dose followed by 50 mg every 12 h). Thirteen days later, the first tigecycline-resistant isolate was detected from an ascites sample (QJJ49) with a tigecycline MIC of 32 mg/L; 19 days later, another tigecycline resistant isolate was detected from a blood sample (QJJ51) with a tigecycline MIC of 32 mg/L. Tigecycline therapy lasted for 19 days, until the resistant phenotype appeared. At the end of the treatment period, the patient expired from multiple organ dysfunction syndrome (MODS).

Bacterial Isolates
------------------

All of the isolates were preliminarily identified using the VITEK 2 system (bioMérieux, France) and were further confirmed by 16S rRNA gene sequencing. Multilocus sequence typing (MLST) of the isolate was analyzed using the BacWGSTdb server with the entire genome sequence ([@B20]).

Antimicrobial Susceptibility Test
---------------------------------

The MICs of tigecycline and colistin were determined using standard broth microdilution tests with fresh (\<12 h) Mueller--Hinton broth (Cation-adjusted, Oxoid LTD, Basingstoke, Hampshire, England). *E. coli* ATCC 25922 was used for quality control ([@B10]). The MICs of other antimicrobial agents were determined using the Etest method. All tests were performed according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). Antimicrobial susceptibility was determined using the breakpoints approved by the CLSI, with the U.S. Food and Drug Administration (FDA) breakpoints used for tigecycline (≤2.0 mg/L, susceptible; 4.0 mg/L, intermediate; and ≥8.0 mg/L, resistant).

Whole Genome Sequencing and Analysis
------------------------------------

Genomic DNA was extracted using a QIAamp DNA MiniKit (Qiagen, Valencia, CA, United States) following the manufacturer's instructions. The genomes were sequenced using the Illumina HiSeq^TM^ X Ten platform (Illumina, Inc., San Diego, CA, United States) following the paired-end 2 bp × 150 bp protocol. The whole genome sequences were assembled using CLC Genomics Workbench 9.0 software (Qiagen, Valencia, CA, United States). Resistance-related genes were analyzed using ResFinder 3.0 with a 90% threshold for gene identification and a 60% minimum length ([@B26]).

The genomic sequence of the initial isolate QJJ29 was used as the reference genome. The reads from the other isolates were mapped against this reference genome using CLC Genomics Workbench 9 software. Basic variants such as single nucleotide polymorphisms (SNPs) and insertion and deletion mutations were predicted by CLC software and the potential mutations were confirmed by PCR and Sanger sequencing with the primers listed in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}. Potential large fragment insertions were also searched by CLC software, but not verified by PCR and sequencing.

Transformation and Conjugation Experiment
-----------------------------------------

DNA fragments carrying the wild-type *tetA* and mutated *tetA* genes were amplified from the tigecycline-susceptible isolate QJJ29 and the tigecycline-resistant isolate QJJ51, respectively, with the primers listed in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}. Following amplification, the amplimer was cloned into plasmid pCR2.1 (Invitrogen, United States) behind the T7 promoter. *E. coli* ATCC 25922 was used for transformation. The effect of the *tetA* mutation on the tigecycline MIC was examined using standard broth microdilution tests.

The transfer capacity of tigecycline resistance was investigated by conjugation experiments ([@B9]). We used the rifampicin-resistant *E. coli* EC600 as a recipient and the rifampicin-susceptible isolates QJJ29 and QJJ51 as donors. Transconjugants were selected on MH agar plates supplemented with tetracycline (32 mg/L) and rifampicin (800 mg/L). The tigecycline MIC of the transconjugants was examined using standard broth microdilution tests. The *tetA* gene was analyzed in the EC600 transconjugants by PCR and Sanger sequencing with the primers *tetA*-Com-F and *tetA*-Com-R (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}).

S1-PFGE and Southern Blot Hybridization
---------------------------------------

Genomic DNA was digested with the S1 enzyme following the protocol of [@B3].

The DNA fragments were transferred to a positively charged nylon membrane (Millipore, United States), hybridized with a DIG-labeled specific probe and detected with an NBT/BCIP color detection kit (Roche, Germany). The hybridization probe was designed to bind within the middle portion of the *tetA* gene and was synthesized using the primers listed in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}.

Nucleotide Sequence Accession Numbers
-------------------------------------

The Whole Genome Shotgun projects for isolates QJJ29 (Accession No. [POUY00000000](POUY00000000)), QJJ36 (Accession No. [POWK00000000](POWK00000000)), QJJ49 (Accession No. [POUX00000000](POUX00000000)), and QJJ51 (Accession No. [POWJ00000000](POWJ00000000)) have been deposited at DDBJ/EMBL/GenBank.

Results
=======

Isolate Characterizations
-------------------------

Four *K. pneumoniae* isolates were isolated from a patient during tigecycline treatment at Sir Run Run Shaw hospital in Zhejiang, China, in 2016. All of the isolates belong to Sequence Type 11 (ST11) and were classified as XDR. According to Illumina sequencing and subsequent mapping, the mapping percentages among the isolates all exceeded 99.6% (i.e., they are clonally consistent). The MICs of the isolates to different antibiotics are presented in **Table [1](#T1){ref-type="table"}**. The initial isolate, QJJ29, was collected from a blood sample on April 23, 2016, the same day tigecycline treatment was initiated. QJJ29 was resistant to carbapenem but susceptible to tigecycline. Six days later, on April 28, 2016, the second isolate, QJJ36, was collected. QJJ36 was also susceptible to tigecycline. Thirteen days after the commencement of tigecycline treatment, on May 5, 2016, the first tigecycline-resistant isolate, QJJ49 with a tigecycline MIC of 32 mg/L, was collected from an ascites sample. On May 11, 2016, the second tigecycline-resistant isolate, QJJ51, was collected from a blood sample. The clinical data of the isolates are listed in **Table [2](#T2){ref-type="table"}**.

###### 

MICs of the QJJ29, QJJ36, QJJ49, and QJJ51 isolates to different antibiotics.

  Isolate   MIC (mg/L)^a^                                                 
  --------- --------------- ----- ----- ----- ------ ------ ------ ------ ----
  QJJ29     ≥256            ≥32   ≥32   ≥32   ≥256   0.25   128    8      1
  QJJ36     ≥256            ≥32   ≥32   ≥32   ≥256   0.25   128    8      1
  QJJ49     ≥256            1     1     ≥32   ≥256   0.25   ≥256   ≥256   32
  QJJ51     ≥256            ≥32   ≥32   ≥32   ≥256   0.25   ≥256   ≥256   32

a

PM, cefepime; IP, imipenem; MP, meropenem; CI, ciprofloxacin; AK, amikacin; CO, colistin; TC, tetracycline; MC, minocycline; TGC, tigecycline.

###### 

Mutations in QJJ51, QJJ49, and QJJ36 compared with QJJ29.

  Isolate   Collection date                 TGC MIC   Days of ongoing TGC treatment   Reference position of the mutation   Gene and product                                        Nucleotide change      Amino acid change
  --------- ------------------------------- --------- ------------------------------- ------------------------------------ ------------------------------------------------------- ---------------------- -------------------
  QJJ29     April 23, 2016 (blood sample)   1 mg/L    TGC treatment started           --                                   --                                                      --                     --
  QJJ36     April 28, 2016 (blood sample)   1 mg/L    6                               QJJ29 contig 1: 189918               Hypothetical protein                                    T1373A                 L458Q
                                                                                      QJJ29 contig 19: 47896               tRNA-Leu                                                C47T                   --
                                                                                      QJJ29 contig 22: 133                 Peptidylprolyl isomerase                                Insertion 712CTC       Insertion 238L
  QJJ49     May 5, 2016                     32 mg/L   13                              QJJ29 contig 1: 189918               Hypothetical protein                                    T1373A                 L458Q
            (ascites sample)                                                          QJJ29 contig 19: 47896               tRNA-Leu                                                C47T                   --
                                                                                      QJJ29 contig 22: 133                 Peptidylprolyl isomerase                                Insertion 712CTC       Insertion 238L
                                                                                      QJJ29 contig 2: 69019                *malT*: transcriptional regulator MalT                  T2483C                 L828P
                                                                                      QJJ29 contig 79: 1641                TetA family tetracycline resistance MFS efflux *Pump*   T751G                  S251A
  QJJ51     May 11, 2016                    32 mg/L   19                              QJJ29 contig 1: 189918               Hypothetical protein                                    T1373A                 L458Q
            (blood sample)                                                            QJJ29 contig 19: 47896               tRNA-Leu                                                C47T                   --
                                                                                      QJJ29 contig 22: 133                 Peptidylprolyl isomerase                                Insertion 712CTC       Insertion 238L
                                                                                      QJJ29 contig 2: 69019                *malT*: transcriptional regulator MalT                  T2483C                 L828P
                                                                                      QJJ29 contig 79: 1641                TetA family tetracycline resistance MFS efflux *pump*   T751G                  S251A
                                                                                      QJJ29 contig 32: 8939                *abiU*: AIPR protein                                    Deletion 178--180GAA   Deletion 60E

Distribution of Resistance Genes
--------------------------------

The resistance genes present in the genomes of the isolates are presented in **Table [3](#T3){ref-type="table"}**. All isolates harbored multiple resistance genes. We identified the aminoglycoside resistance gene *rmtB*; the beta-lactam resistance genes *bla*~TEM-1B~, *bla*~CTX-M-65~, *bla*~SHV\ -2~, and *bla*~KPC-2~; the fluoroquinolone resistance gene *qnrS1*; the fosfomycin resistance genes *fosA* and *fosA3*; the lincosamide resistance gene *lnu(A)*; the phenicol resistance gene *catA2*; the sulphonamide resistance gene *sul2*; the trimethoprim resistance gene *dfrA14*; and the tetracycline resistance gene *tetA*. Isolates QJJ51 and QJJ49 had an additional *lnu(A)* gene that was not present in QJJ29 and QJJ36, and isolate QJJ49 lacked the *bla*~KPC-2~ gene and was susceptible to imipenem and meropenem.

###### 

Distribution of resistance genes in isolates QJJ29, QJJ36, QJJ49, and QJJ51.

  Antimicrobial pattern        Resistance gene   Isolates             
  ---------------------------- ----------------- ---------- ---- ---- ----
  Aminoglycoside resistance    *rmtB*            \+         \+   \+   \+
  Beta-lactam resistance       *bla*~TEM-1B~     \+         \+   \+   \+
                               *bla*~CTX-M-65~   \+         \+   \+   \+
                               *bla*~SHV\ -2~    \+         \+   \+   \+
                               *bla*~KPC-2~      \+         \+        \+
  Fluoroquinolone resistance   *qnrS1*           \+         \+   \+   \+
  Fosfomycin resistance        *fosA*            \+         \+   \+   \+
                               *fosA3*           \+         \+   \+   \+
  Lincosamide resistance       *lnu(A)*                          \+   \+
  Phenicol resistance          *catA2*           \+         \+   \+   \+
  Sulphonamide resistance      *sul2*            \+         \+   \+   \+
  Trimethoprim resistance      *dfrA14*          \+         \+   \+   \+
  Tetracycline resistance      *tetA*            \+         \+   \+   \+

Genomic Analysis
----------------

According to the mapping analysis, the QJJ36, QJJ49, and QJJ51 isolates all exhibited greater than 99.6% similarity to the reference genome (QJJ29). Three, five, and six mutation sites were confirmed in QJJ36, QJJ49, and QJJ51, respectively (**Table [2](#T2){ref-type="table"}**). The three mutations in QJJ36 (QJJ29 contig 1: 189918; QJJ29 contig 19: 47896; and QJJ29 contig 22: 133) were all present in QJJ49 and QJJ51. The tigecycline MIC of QJJ36 was the same as that of QJJ29. One point mutation in *tetA* (QJJ29 contig 79: 1641) was found in both QJJ49 and QJJ51. This mutation (T751G) results in an amino acid substitution (S251A). One, six, and four potential large fragment insertions were found in QJJ36, QJJ49, and QJJ51, respectively. Most of them were located in intergenic region. Only one gene *rmpA* (in isolate QJJ49) was truncated by the insertion (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}).

Effects of the *tetA* Mutation on Tigecycline Resistance
--------------------------------------------------------

The results of the complementation experiment are presented in **Table [4](#T4){ref-type="table"}**. When *E. coli* ATCC 25922 was transformed with the mutated *tetA* gene (25922/pCR2.1-*tetA*+), its tigecycline MIC increased from 0.125 to 8 mg/L, its tetracycline MIC increased from 1 to 128 mg/L, and its minocycline MIC increased from 1 to 16 mg/L. When 25922 was transformed with the wild-type *tetA* gene (25922/pCR2.1-*tetA*), its tigecycline MIC increased only from 0.125 to 0.5 mg/L, while its tetracycline MIC increased from 1 to 64 mg/L and its minocycline MIC increased from 1 to 4 mg/L. No MIC change was found in 25922 when it was transformed with the empty pCR2.1 vector (25922/pCR2.1).

###### 

Changes in the tetracycline, minocycline, and tigecycline MICs during the transformation and conjugation experiments.

  Strain                          Tetracycline   Minocycline   Tigecycline
  ------------------------------- -------------- ------------- -------------
  25922                           1              1             0.125
  25922/pCR2.1                    1              1             0.125
  25922/pCR2.1-*tetA*             64             4             0.5
  25922/pCR2.1-*tetA*+            128            16            8
  QJJ29 (donor)                   128            8             1
  QJJ51 (donor)                   ≥256           ≥256          32
  EC600 (recipient)               1              1             0.125
  EC600 transconjugant of QJJ29   64             4             0.5
  EC600 transconjugant of QJJ51   128            16            4

Conjugation of the Tigecycline Resistance Factor
------------------------------------------------

The transfer capacity of tigecycline resistance was confirmed by a conjugation experiment. The tigecycline MIC increased 32-fold in the EC600 transconjugant of QJJ51 compared with that of the parental strain EC600 (from 0.125 to 4 mg/L); furthermore, the tetracycline MIC increased from 1 to 128 mg/L and the minocycline MIC increased from 1 to 16 mg/L (**Table [4](#T4){ref-type="table"}**). Conversely, in the EC600 transconjugant of QJJ29, the tigecycline MIC increased only from 0.125 to 0.5 mg/L while the tetracycline MIC increased from 1 to 64 mg/L and the minocycline MIC increased from 1 to 4 mg/L compared with the parental strain EC600.

Southern Blot Hybridization of the *tetA* Gene
----------------------------------------------

The *tetA* gene was determined to be transferred by conjugation by southern blot hybridization and PCR assays. The *tetA* gene was located on a transferable plasmid with a size of ca. 65 kb in all the isolates detected (**Figure [1](#F1){ref-type="fig"}**). From the PCR and Sanger sequencing results, the EC600 transconjugant of QJJ51 harbored the same mutant-type *tetA* gene as isolate QJJ51.

![Analysis of *tetA* localization using S1-PFGE and southern blot hybridization. **(A)** S1-PFGE profiles and **(B)** southern blot hybridization with a *tetA* probe. M, *Salmonella enterica* H9812 DNA digested with *XbaI*, used as a molecular marker (kb); lanes 1--6, QJJ29, QJJ36, QJJ49, QJJ51, EC600 transconjugant of QJJ51, and EC600, respectively.](fmicb-09-00648-g001){#F1}

Discussion
==========

In this study, tigecycline resistance was monitored in a 56-year-old female patient infected with CRKP during tigecycline treatment. At the outset of her treatment, the strain was found to be susceptible to tigecycline; 13 days later, the first tigecycline resistant isolate was detected, and it possessed a high tigecycline MIC (32 mg/L).

Over-expression of RND efflux pumps and mutations in the ribosomal S10 protein (*rpsJ*) have been the widely accepted mechanisms that result in decreased tigecycline susceptibility in *K. pneumoniae* ([@B22], [@B21]; [@B5]; [@B19]; [@B25]; [@B4]; [@B10]). However, the tigecycline resistant isolates (QJJ49 and QJJ51) collected in this study had neither over-expressed RND efflux pumps AcrAB and OqxAB (the expression levels of the efflux pump genes were detected by qRT-PCR, Supplementary Table [S3](#SM3){ref-type="supplementary-material"}) nor *rpsJ* gene mutations. One mutation in the *tetA* gene (S251A) was uncovered through WGS and analysis. Subsequent transformation and conjugation experiments revealed that the *tetA* mutation was responsible for the development of tigecycline resistance in these isolates.

The wild-type *tetA* gene was observed to slightly decrease the sensitivity to tigecycline in *Salmonella enterica* clinical isolates by [@B1]. In our study, transformation of the wild-type *tetA* gene into *E. coli* ATCC 25922 increased the tigecycline MIC from 0.125 to 0.5 mg/L (**Table [4](#T4){ref-type="table"}**). This phenomenon coincides with that of Akiyama's.

[@B14] reported that *tetA* evolution causes decreased sensitivity to tigecycline in *E. coli* *in vitro*. They created libraries of mutagenized *tetA* sequences through separate, error-prone PCR assays, which were then cloned into the pBAD30 vector and electroporated into *E. coli NEB5α*. Subsequently, the researchers selected 53 independent mutants with elevated tigecycline MICs. The most common amino acid substitution identified was G300E. Other frequent changes were identified more than once in the independent mutants including S251A. In another report, [@B7] also frequently isolated mutated *tetA* genes in tigecycline-resistant *K. pneumoniae*.

The current study is the first to provide direct *in vivo* evidence that changes in the *tetA* gene can lead to tigecycline treatment failure in patients infected with CRKP clinical strains. Distinct from Linkevicius's study, we discovered that the S251A mutation resulted in high-level tigecycline resistance in CRKP strains and *E. coli* ATCC 25922, and their tetracycline and minocycline MICs also increased (**Tables [1](#T1){ref-type="table"}**, **[4](#T4){ref-type="table"}**). Furthermore, our conjugation experiment confirmed the transfer capacity of tigecycline resistance, which was found to be mediated by the mutated *tetA* through a transferable plasmid of ca. 65 kb. Tigecycline is regarded as a last resort treatment for CRKP infections. This finding serves as a therapeutic warning as the *tetA* gene is frequently carried by CRKP strains. Under selective pressure from tigecycline, the *tetA* mutation may occur and lead to treatment failure. This transfer capacity is also a threat to the service life of tigecycline; the more the *tetA* mutates and evolves toward tigecycline resistance, the more likely it will become a horizontally transferrable resistance gene for tigecycline resistance.
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